Active	Status	Sponsor type	Region	Phase	Filter
3 Active 3 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Thomas, Haydn Mikel
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)	Active, not recruiting	4	288	Europe, US	Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo	Shire, Takeda Development Center Americas, Inc.	Attention Deficit Hyperactivity Disorder	06/27	06/27
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection	Completed	2	63	US	TNX-102 SL, Placebo SL Tablet	Tonix Pharmaceuticals, Inc.	Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID	07/23	07/23
NCT05860959: SUBLOCADE Long-term Outcomes	Recruiting	N/A	1200	Europe, Canada, US, RoW		Indivior Inc.	Opioid Use Disorder	08/27	08/27